Organogenesis Inc. (ORGO)
NASDAQ: ORGO
· Real-Time Price · USD
4.72
0.02 (0.43%)
At close: Aug 15, 2025, 3:59 PM
4.80
1.59%
After-hours: Aug 15, 2025, 05:16 PM EDT
0.43% (1D)
| Bid | 4.45 |
| Market Cap | 599.4M |
| Revenue (ttm) | 458.76M |
| Net Income (ttm) | -18.63M |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -33.75 |
| Forward PE | 22.62 |
| Analyst | Hold |
| Ask | 4.95 |
| Volume | 459,257 |
| Avg. Volume (20D) | 894,388 |
| Open | 4.71 |
| Previous Close | 4.70 |
| Day's Range | 4.69 - 4.89 |
| 52-Week Range | 2.45 - 6.71 |
| Beta | 1.77 |
About ORGO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ORGO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ORGO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Organogenesis Inc. is scheduled to release its earnings on
Nov 11, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+0.44%
Organogenesis Holdings shares are trading lower af...
Unlock content with
Pro Subscription
3 months ago
-42.7%
Organogenesis Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.
1 week ago · fool.com
ORGO Sales Drop 23%ORGO Sales Drop 23%
2 months ago · seekingalpha.com
Organogenesis Holdings: ReNu And New LCD Offer A Rebound ScenarioORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by Septemb...